Comprehensive metabolic correction in cognitive impairment: theoretical background for using citicoline and Bacopa monnieri combination

Authors

  • T.M. Slobodin Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2224-0713.16.7.2020.218247

Keywords:

cognitive impairment, network-based approach, Bacopa monnieri, citicoline, combination

Abstract

In the past few decades, genetic and biochemical researches have revealed an extensive network of molecular and metabolic pathways involved in pathogenesis of cognitive decline, suggesting that a multi-target, network-based therapeutic approach, rather than a single target-based approach, may be potentially more effective for the treatment. This review summarizes the current evidence base of multiple neuromolecular mechanisms of cognitive enhancing action of Bacopa monnieri, a medicinal Ayurvedic herb, and its possible beneficial interactions with other well-known neuroprotective agent citicoline. Current experimental evidence suggests that Bacopa monnieri acts via the following mechanisms: antioxidant neuroprotection, increased cerebral blood flow, β-amyloid reduction, acetylcholinesterase inhibition and/or choline acetyltransferase activation, and modulation of other neurotransmitter systems (norepinephrine, 5-hydroxytryptamine, dopamine). Several randomized, double-blind, placebo-controlled trials have substantiated procognitive action of Bacopa monnieri in humans. Nootropic properties of Bacopa monnieri, at least partly, interfere with neuroprotective mechanisms of citicoline, creating potential additive effect in the correction of cognitive impairment of different (degenerative, vascular or both) origin.

References

Zanotta D., Puricelli S., Bonoldi G. Cognitive effects of a dietary supplement made from extract of Bacopa monnieri, astaxanthin, phosphatidylserine, and vitamin E in subjects with mild cognitive impairment: a noncomparative, exploratory clinical study. Neuropsychiatr. Dis. Treat. 2014, Feb 3. 10. 225-30. doi: 10.2147/NDT.S51092. eCollection 2014.

Lo J.W. et al. Profile of and risk factors for poststroke cognitive impairment in diverse ethnoregional groups. Neurology. December 10, 2019. 93(24). DOI: https://doi.org/10.1212/WNL.0000000000008612.

Bredesen D.E. Reversal of cognitive decline: a novel therapeutic program. Aging (Albany NY). 2014, Sep. 6(9). 707-17.

Petersen R.C., Lopez O., Armstrong M.J. et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018, Jan 16. 90(3). 126-135. doi: 10.1212/WNL.0000000000004826. Epub 2017 Dec 27.

Jeyasri R., Muthuramalingam P., Suba V., Ramesh M., Chen J.T. Bacopa monnieri and Their Bioactive Compounds Inferred Multi-Target Treatment Strategy for Neurological Diseases: A Cheminformatics and System Pharmacology Approach. Biomolecules. 2020, Apr 2. 10(4). pii: E536. doi: 10.3390/biom10040536.

Dubey T., Chinnathambi S. Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer's disease. Arch. Biochem. Biophys. 2019, Nov 15. 676. 108153. doi: 10.1016/j.abb.2019.108153. Epub 2019 Oct 14.

Kumar N. et al. Efficacy of Standardized Extract of Bacopa monnieri (Bacognize®) on Cognitive Functions of Medical Students: A Six-Week, Randomized Placebo-Controlled Trial. Evid. Based Complement Alternat. Med. 2016. 2016. 4103423. Published online 2016, Oct 10. doi: 10.1155/2016/4103423.

Aguiar S., Borowski T. Neuropharmacological Review of the Nootropic Herb Bacopa monnieri. Rejuvenation Res. 2013, Aug. 16(4). 313-326. doi: 10.1089/rej.2013.1431.

Russo A., Izzo A. A., Borrelli F., Renis M., Vanella A. Free radical scavenging capacity and protective effect of Bacopa monniera L. on DNA damage. Phytotherapy Research. 2003. 17(8). 870-875. doi: 10.1002/ptr.1061.

Tripathi Y. B., Chaurasia S., Tripathi E., Upadhyay A., Dubey G.P. Bacopa monniera Linn. as an antioxidant: mechanism of action. Indian Journal of Experimental Biology. 1996. 34(6). 523-526.

Rastogi M., Ojha R., Prabu P.C., Devi D.P., Agrawal A., Dubey G.P. Amelioration of age associated neuroinflammation on long term bacosides treatment. Neurochem. Res. 2012. 37. 869-874.

Kamkaew N., Scholfield N., Ingkaninan K., Taepavarapruk N., Chootip K. Bacopa monnieri increases cerebral blood flow in rat independent of blood pressure. Phytother. Res. 2013. 27. 135-138.

Kamkaew N., Scholfield C.N., Ingkaninan K., Maneesai P., Parkington H.C., Tare M., Chootip K. Bacopa monnieri and its constituents is hypotensive in anaesthetized rats and vasodilator in various artery types. J. Ethnopharmacol. 2011. 137. 790-795.

Mathew M., Subramanian M. Evaluation of the anti-amyloidogenic potential of nootropic herbal extracts in vitro. IJPSR. 2012. 3. 4276-4280.

Holcomb L.A., Dhanasekaran M., Hitt A.R., Young K.A., Riggs M., Manyam B.V. Bacopa monniera extract reduces amyloid levels in PSAPP mice. J. Alzheimer’s Dis. 2006. 9. 243-251.

Limpeanchob N., Jaipan S., Rattanakaruna S., Phrompittayarat W., Ingkaninan K. Neuroprotective effect of Bacopa monnieri on beta-amyloid-induced cell death in primary cortical culture. J. Ethnopharmacol. 2008. 30. 120. 112-117.

Uabundit N., Wattanathorn J., Mucimapura S., Ingkaninan K. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer’s disease model. J. Ethnopharmacol. 2010. 8. 127. 26-31.

Rajan Е.K., Singh H.K., Parkavi A., Prisila D.C. Attenuation of 1-(m-chlorophenyl) biguanide induced hippocampus-dependent memory impairment by a standardised extract of Bacopa monniera. Neurochem. Res. 2011. 36. 2136-2144.

Vollala V.R., Upadhya S., Nayak S. Enhancement of basolateral amygdaloid neuronal dendritic arborization following Bacopa monniera extract treatment in adult rats. Clinics (Sao Paulo). 2011. 66. 663-671.

Secades J.J. Citicoline in the Treatment of Cognitive Impairment. J. Neurol. Exp. Neurosci. 2019. 5(1). 14-26.

Babb S.M., Wald L.L., Cohen B.M., Villafuerte R.A., Gruber S.A., Yurgelun-Todd D.A., Renshaw P.F. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology (Berl). 2002. 161. 248-54.

Grieb P. Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues. CNS Drugs. 2014. 28. 185-193. DOI 10.1007/s40263-014-0144-8.

Adibhatla R.M., Hatcher J.F. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J. Neurosci Res. 2003. 73. 308-15.

Weiss G.B. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci. 1995. 56. 637-60.

Petkov V.D., Stancheva S.L., Tocuschieva L., Petkov V.V. Changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine (experiments on rats). Gen. Pharmacol. 1990. 21. 71-75.

Donmez G., Outeiro T.F. SIRT1 and SIRT2: Emerging targets in neurodegeneration. EMBO Mol. Med. 2013. 5. 344-352.

Pase M.P., Kean J., Sarris J., Neale C., Scholey A.B., Stough C. The cognitive-enhancing effects of bacopa monnieri: a systematic review of randomized, controlled human clinical trials. Journal of Alternative and Complementary Medicine. 2012. 18(7). 647-652. doi: 10.1089/acm.2011.0367.

Neale C., Camfield D., Reay J., Stough C., Scholey A. Cognitive effects of two nutraceuticals Ginseng and Bacopa benchmarked against modafinil: A review and comparison of effect sizes. Br. J. Clin. Pharmacol. 2013 Mar. 75(3). 728-37. doi: 10.1111/bcp.12002.

Fioravanti M., Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst. Rev. 2005. Apr 18 (2). CD000269.

Fioravanti M., Buckley A.E. Citicoline (Cognizin) in the treatment of cognitive impairment. Clin. Interv. Aging. 2006 Sep. 1(3). 247-251. Published online 2006 Sep. doi: 10.2147/ciia.2006.1.3.247.

Cotroneo A.M. et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin. Interv. Aging. 2013. 8. 131-137. Published online 2013, Feb 5. doi: 10.2147/CIA.S38420

Gareri P., Castagna A. Citicoline as Add-On Treatment in Alzheimer’s Disease: Tips from the Citicholinage Study. J. Alzheimers Dis. Parkinsonism. 2017. 7. 353. doi: 10.4172/2161-0460.1000353.

Gareri P., Cotroneo A.M., Putignano S. The Citimem study: citicoline plus memantine in aged patients affected with Alzheimer’s disease and mixed dementia study. preliminary data. Presented at: 2018 Alzheimer’s Association International Conference. July 22–26, 2018. Chicago, IL. Abstract 24105.

Published

2020-10-01

Issue

Section

To practicing Neurologist